ArticleScience (New York, N.Y.)2008
A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence.
Article in Science (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
231 citing papers in PubMed, 491 citations in OpenAlex.
- Antimicrobial activity of Vepris salicifolia leaf essential oil and δ-cadinene: in vitro evaluation and in silico mechanistic insights into δ-cadinene.Tropical medicine and health · 2026Article
- Chemical Profiling and Antimicrobial Activity of the Leaf Essential Oil ofInternational journal of molecular sciences · 2026Article
- Gramicidin D as a Multi-Target Antimicrobial Against Staphylococcus aureus: Biofilm Disruption, Virulence Attenuation, Antibiotic Potentiation, and Protein-Peptide Docking Insight.Probiotics and antimicrobial proteins · 2026Article
- Comparative Structural Modeling Suggests Distinct Signatures of Conformational Plasticity and Surface Physicochemistry in Phytoene Synthase and Dehydrosqualene Synthase.Molecules (Basel, Switzerland) · 2026Article
- Structure-activity relationship and molecular docking analysis of novel arylhydrazones of imidazodiazabicycloalkanones with antibacterial properties.Molecular diversity · 2026Article
- Novel antimicrobial and antiangiogenic properties from riparin-type benzamides: synthesis, biological evaluation, and docking analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Bacterial biosurfactant-reinforced chitooligosaccharide/polyvinyl alcohol hydrogels accelerate methicillin-resistantAsian journal of pharmaceutical sciences · 2026Article
- Pharmacophore- and QSAR-guided discovery of natural product inhibitors targeting dehydrosqualene synthase in Staphylococcus aureus.PloS one · 2026Article
- Selective bioactive effects ofFrontiers in pharmacology · 2026Article
- Attenuation ofAntibiotics (Basel, Switzerland) · 2025Article
- Master transcriptional regulator SaeS inVirulence · 2025Article
- PLiCat: decoding protein-lipid interactions by large language model.Briefings in bioinformatics · 2025Article
- Cholesterol sensing by the SCAP-FAM134B complex regulates ER-phagy and STING innate immunity.Nature cell biology · 2025Article
- Enhanced On-Demand Antibacterial Platform Based on Triboelectric-Nanogenerator-Induced Electrical Stimulation of CuACS applied materials & interfaces · 2025Article
- Synthesis and Antimicrobial Evaluation of (+)-Neoisopulegol-Based Amino and Thiol Adducts.International journal of molecular sciences · 2025Article
- Mechanistic insights into the multitarget synergistic efficacy of farrerol and β-lactam antibiotics in combating methicillin-resistantAntimicrobial agents and chemotherapy · 2025Article
- Non-Membrane Active Peptide Resensitizes MRSA to β-Lactam Antibiotics and Inhibits S. aureus Virulence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Repurposing Diflunisal as an Antivirulence Agent AgainstInfectious microbes & diseases · 2025Article
- Article
- Novel inhibition ofApplied and environmental microbiology · 2025Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Staphylococcus aureus produces hospital- and community-acquired infections, with methicillin-resistant S. aureus posing a serious public health threat. The golden carotenoid pigment of S. aureus, staphyloxanthin, promotes resistance to reactive oxygen species and host neutrophil-based killing, and early enzymatic steps in staphyloxanthin production resemble those for cholesterol biosynthesis. We determined the crystal structures of S. aureus dehydrosqualene synthase (CrtM) at 1.58 angstrom resolution, finding structural similarity to human squalene synthase (SQS). We screened nine SQS inhibitors and determined the structures of three, bound to CrtM. One, previously tested for cholesterol-lowering activity in humans, blocked staphyloxanthin biosynthesis in vitro (median inhibitory concentration approximately 100 nM), resulting in colorless bacteria with increased susceptibility to killing by human blood and to innate immune clearance in a mouse infection model. This finding represents proof of principle for a virulence factor-based therapy against S. aureus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.